Psychedelics for major depression—From controlled research settings into broader clinical use

Mihai Avram; Stefan Borgwardt

doi:10.1016/j.xcrm.2025.102361

Psychedelics for major depression—From controlled research settings into broader clinical use

Mihai Avram^*, Stefan Borgwardt

^*Corresponding author for this work

Clinic of Psychiatry and Psychotherapy

Abstract

Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms—from receptor-level pharmacology to subjective experience and context—remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future research.

Original language	English
Article number	102361
Journal	Cell Reports Medicine
Volume	6
Issue number	9
DOIs	https://doi.org/10.1016/j.xcrm.2025.102361
Publication status	Published - 16.09.2025

Access to Document

10.1016/j.xcrm.2025.102361

Cite this

@article{edf38765d7c84910bf3d87cb0445dc51,

title = "Psychedelics for major depression—From controlled research settings into broader clinical use",

abstract = "Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms—from receptor-level pharmacology to subjective experience and context—remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future research.",

author = "Mihai Avram and Stefan Borgwardt",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s)",

year = "2025",

month = sep,

day = "16",

doi = "10.1016/j.xcrm.2025.102361",

language = "English",

volume = "6",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Psychedelics for major depression—From controlled research settings into broader clinical use

AU - Avram, Mihai

AU - Borgwardt, Stefan

PY - 2025/9/16

Y1 - 2025/9/16

N2 - Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms—from receptor-level pharmacology to subjective experience and context—remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future research.

AB - Psychedelics have shown promising antidepressant effects in recent phase 2 randomized controlled trials, with phase 3 studies underway. While therapeutic outcomes are encouraging, the underlying mechanisms—from receptor-level pharmacology to subjective experience and context—remain only partially understood. We highlight clinical and mechanistic advances and outline priorities for future research.

UR - https://www.scopus.com/pages/publications/105015718569

U2 - 10.1016/j.xcrm.2025.102361

DO - 10.1016/j.xcrm.2025.102361

M3 - Comments/Debates

C2 - 40961925

AN - SCOPUS:105015718569

SN - 2666-3791

VL - 6

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 9

M1 - 102361

ER -

Psychedelics for major depression—From controlled research settings into broader clinical use

Abstract

Access to Document

Other files and links

Fingerprint

Cite this